<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00631358</url>
  </required_header>
  <id_info>
    <org_study_id>ORE 14351</org_study_id>
    <nct_id>NCT00631358</nct_id>
    <nct_alias>NCT00806702</nct_alias>
  </id_info>
  <brief_title>Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to quantify the change in expression of biomarkers on
      the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Levels of Biomarkers After Dosing With Maxidex</measure>
    <time_frame>Baseline to 2 weeks</time_frame>
    <description>Biomarkers are an indicatior of inflammation. In this study, the level of biomarkers before and after anti-inflammatory treatment (Maxidex) is measured for the treatment group. In the control group, the biomarker level is measured at baseline and 2 weeks later. ddCt (Delta-Delta-Ct) is the number of polymerase chain reaction (PCR) cycles required to generate a quantifiable number.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Biomarker Expression and Ocular Symptoms</measure>
    <time_frame>Baseline to 2 weeks</time_frame>
    <description>Correlation factor: tumor necrosis factor (TNF) messenger RNA (mRNA) vs. OSDI (Ocular Surface Disease Index).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Biomarker Expression and Tear Film Break up Time</measure>
    <time_frame>Baseline to 2 weeks</time_frame>
    <description>Correlation factor:
TNFmRNA vs. TFBUT (Tear Film Break-up Time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Biomarker Expression and NaFl (Sodium Fluorescein) Staining</measure>
    <time_frame>Baseline to 2 weeks</time_frame>
    <description>Correlation factor:
TNFmRNA vs. NaFl staining</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Biomarker Expression and the Schirmer Test</measure>
    <time_frame>Baseline to 2 weeks</time_frame>
    <description>Correlation factor: TNFmRNA vs. Schirmer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Maxidex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maxidex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Healthy normal control group receiving no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maxidex</intervention_name>
    <description>Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily</description>
    <arm_group_label>Maxidex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment</intervention_name>
    <description>Healthy normal control group receiving no treatment</description>
    <arm_group_label>No treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria of Sjorgren's Population:

        Inclusion Criteria:

          -  17 years or older

          -  LogMar visual acuity of 0.6 or better

          -  Ocular inflammation associated with Sjogren's Syndrome

        Exclusion Criteria:

          -  Has had an adverse reaction to either topical of systemic steroids in the past

          -  Has diabetes (type 1 or 2)

          -  Has glaucoma or evidence of ocular hypertension in either eye or treatment of either
             within six months of Visit 1

          -  Has worn contact lenses within one week prior to Visit 1

          -  Has received ocular prescription therapy in the last 30 days

          -  Has active ocular infections or inflammation not associated with Sjogren's Syndrome.

          -  Has any finding in the vitreous, macula, retina or choroid that show signs of
             inflammation and/or any structural change that in the opinion of the investigator is
             considered abnormal or unstable for that participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Toronto</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterloo</name>
      <address>
        <city>Waterloo</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2008</study_first_submitted>
  <study_first_submitted_qc>February 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <results_first_submitted>February 17, 2010</results_first_submitted>
  <results_first_submitted_qc>March 29, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 12, 2010</results_first_posted>
  <last_update_submitted>March 29, 2010</last_update_submitted>
  <last_update_submitted_qc>March 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ravaughn Williams, OD, MS</name_title>
    <organization>Alcon</organization>
  </responsible_party>
  <keyword>Ocular inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited via flyers, newspaper advertisements, radio advertisements and chart review in the doctorsâ€™ office.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Maxidex</title>
          <description>Maxidex 1 drop in each eye 2 times daily</description>
        </group>
        <group group_id="P2">
          <title>No Treatment</title>
          <description>Healthy normal control group receiving no treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Maxidex</title>
          <description>Maxidex 1 drop in each eye 2 times daily</description>
        </group>
        <group group_id="B2">
          <title>No Treatment</title>
          <description>Healthy normal control group receiving no treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Levels of Biomarkers After Dosing With Maxidex</title>
        <description>Biomarkers are an indicatior of inflammation. In this study, the level of biomarkers before and after anti-inflammatory treatment (Maxidex) is measured for the treatment group. In the control group, the biomarker level is measured at baseline and 2 weeks later. ddCt (Delta-Delta-Ct) is the number of polymerase chain reaction (PCR) cycles required to generate a quantifiable number.</description>
        <time_frame>Baseline to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maxidex</title>
            <description>Maxidex 1 drop in each eye 2 times daily</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Healthy normal control group receiving no treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Biomarkers After Dosing With Maxidex</title>
          <description>Biomarkers are an indicatior of inflammation. In this study, the level of biomarkers before and after anti-inflammatory treatment (Maxidex) is measured for the treatment group. In the control group, the biomarker level is measured at baseline and 2 weeks later. ddCt (Delta-Delta-Ct) is the number of polymerase chain reaction (PCR) cycles required to generate a quantifiable number.</description>
          <units>ddCt (Delta-Delta-Ct)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.244" spread="1.08"/>
                    <measurement group_id="O2" value="-0.29" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.033" spread="1.06"/>
                    <measurement group_id="O2" value="-0.33" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Biomarker Expression and Ocular Symptoms</title>
        <description>Correlation factor: tumor necrosis factor (TNF) messenger RNA (mRNA) vs. OSDI (Ocular Surface Disease Index).</description>
        <time_frame>Baseline to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maxidex</title>
            <description>Maxidex 1 drop in each eye 2 times daily</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Healthy normal control group receiving no treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Biomarker Expression and Ocular Symptoms</title>
          <description>Correlation factor: tumor necrosis factor (TNF) messenger RNA (mRNA) vs. OSDI (Ocular Surface Disease Index).</description>
          <units>Correlation factor</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09"/>
                    <measurement group_id="O2" value="-0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Biomarker Expression and Tear Film Break up Time</title>
        <description>Correlation factor:
TNFmRNA vs. TFBUT (Tear Film Break-up Time)</description>
        <time_frame>Baseline to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maxidex</title>
            <description>Maxidex 1 drop in each eye 2 times daily</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Healthy normal control group receiving no treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Biomarker Expression and Tear Film Break up Time</title>
          <description>Correlation factor:
TNFmRNA vs. TFBUT (Tear Film Break-up Time)</description>
          <units>Correlation factor</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16"/>
                    <measurement group_id="O2" value="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Biomarker Expression and NaFl (Sodium Fluorescein) Staining</title>
        <description>Correlation factor:
TNFmRNA vs. NaFl staining</description>
        <time_frame>Baseline to 2 weeks</time_frame>
        <population>No data available for the no treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Maxidex</title>
            <description>Maxidex 1 drop in each eye 2 times daily</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Healthy normal control group receiving no treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Biomarker Expression and NaFl (Sodium Fluorescein) Staining</title>
          <description>Correlation factor:
TNFmRNA vs. NaFl staining</description>
          <population>No data available for the no treatment group.</population>
          <units>Correlation factor</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Biomarker Expression and the Schirmer Test</title>
        <description>Correlation factor: TNFmRNA vs. Schirmer</description>
        <time_frame>Baseline to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maxidex</title>
            <description>Maxidex 1 drop in each eye 2 times daily</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Healthy normal control group receiving no treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Biomarker Expression and the Schirmer Test</title>
          <description>Correlation factor: TNFmRNA vs. Schirmer</description>
          <units>Correlation Factor</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02"/>
                    <measurement group_id="O2" value="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse reporting began once the patient enrolled into the study and went on for the duration of the study (6 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Maxidex</title>
          <description>Maxidex 1 drop in each eye 2 times daily</description>
        </group>
        <group group_id="E2">
          <title>No Treatment</title>
          <description>Healthy normal control group receiving no treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor shall be furnished with copies of any proposed disclosure as follows: Published abstracts will be submitted to the sponsor one month prior to submission allowing the sponsor three weeks to respond. Presentations will be submitted to the sponsor one moth prior to submission allowing the sponsor three weeks to respond. Publications will be submitted to the sponsor two months prior to submission allowing the sponsor two months to respond.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Labs</organization>
      <phone>1-888-451-3937; 1-817-568-6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

